<DOC>
	<DOCNO>NCT00595686</DOCNO>
	<brief_summary>Hsp90 chemical body involved promotion cancer . SNX-5422 experimental drug block Hsp90 . It evaluate safety efficacy patient cancer .</brief_summary>
	<brief_title>Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>&gt; 18 year old Karnofsky performance status &gt; 60 confirmed hematological malignancy refractory available therapy therapy available adequate hepatic , renal hematological function CNS malignancy risk prolong QT interval significant GI/liver disease serious concurrent illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hematologic Malignancies Hsp90 Hematologic Malignancy</keyword>
</DOC>